Archived News Releases

Pacira BioSciences Announces Positive Topline Data from Phase 3 Study of EXPAREL as a Single-dose Sciatic Nerve Block in the Popliteal Fossa for Bunionectomy

09/21/22

Pacira Receives Positive CHMP Opinion for EXPAREL® for the Treatment of Postsurgical Pain in Children Aged 6 or Older

09/20/22

Pacira BioSciences Reports Preliminary Net Product Sales of $59.1 Million for August 2022

09/13/22

Pacira BioSciences Announces Positive Topline Data from Phase 3 Study of EXPAREL as a Single-dose Femoral Nerve Block in the Adductor Canal for Total Knee Arthroplasty

09/07/22

Pacira BioSciences Reports Preliminary Net Product Sales of $50.2 Million for July 2022

08/10/22

NFL Alumni Association and Pacira BioSciences Team Up to Educate Athletes and Communities About Non-Opioid Options to Manage Pain

08/09/22

Pacira BioSciences Reports Second Quarter 2022 Financial Results

08/03/22

Pacira BioSciences to Participate in Fireside Chat at the 2022 Wedbush PacGrow Healthcare Virtual Conference

08/02/22

Pacira to Report Second Quarter 2022 Financial Results on Wednesday August 3, 2022

07/27/22

Pacira BioSciences Reports Preliminary Second Quarter 2022 Revenue of $169.4 Million

07/14/22

National Safety Council and Pacira BioSciences Partner to Launch an Employee-Based Program Focused on Opioid Use and Misuse

06/16/22

Pacira BioSciences Reports Preliminary Net Product Sales for EXPAREL and iovera° of $46.0 Million for May 2022

06/14/22

Pacira BioSciences to Participate in Fireside Chat at the Jefferies Healthcare Conference

06/02/22

Pacira BioSciences Reports Preliminary Net Product Sales for EXPAREL and iovera° of $45.8 Million for April 2022

05/12/22

Pacira BioSciences to Present at Two Healthcare Conferences in May

05/10/22

Pacira BioSciences Reports First Quarter 2022 Financial Results

05/04/22

Pacira to Report First Quarter 2022 Financial Results on Wednesday May 4, 2022

04/27/22

Pacira BioSciences Reports Preliminary Revenues of $157.4 to $158.4 Million for the First Quarter of 2022

04/12/22

Pacira BioSciences to Participate in Fireside Chat at the 21st Annual Needham Virtual Healthcare Conference

04/05/22

Pacira BioSciences Reports Preliminary Net Product Sales for EXPAREL and iovera° of $42.6 Million for February 2022

03/15/22

Pacira BioSciences to Participate in Fireside Chat at the Barclays Global Healthcare Conference

03/09/22

Pacira BioSciences Reports Full-Year and Fourth Quarter 2021 Financial Results

02/24/22

Pacira to Report 2021 Financial Results on Thursday February 24, 2022

02/16/22

Pacira BioSciences Reports Preliminary Net Product Sales for EXPAREL and iovera° of $37.3 Million for January 2022

02/15/22

Pacira Reports Preliminary Unaudited Total Revenue for 2021 of $540.7 Million to $541.7 Million

01/06/22

Pacira BioSciences to Present at the 40th Annual J.P. Morgan Healthcare Conference

01/03/22